Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | VCP | P55072 | 1/20 | 0.46 |
| ▸ | OGA | O60502 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2848210 | 0.94 | HRH3 (0.48) | HRH3L3MBTL1RAB9AP2RY12MAPT | |
| SCHEMBL2828583 | 0.90 | HRH3 (0.46) | HRH3L3MBTL1RAB9AMAPTKDM4E | |
| Cyclohexane SCHEMBL2828762 | 0.83 | L3MBTL1 (0.52) | HRH3L3MBTL1RAB9AMAPTKDM4E | |
| SCHEMBL2829488 | 0.81 | ALDH1A1 (0.52) | HRH3L3MBTL1RAB9AP2RY12MAPT | |
| SCHEMBL2825726 | 0.80 | FGFR3 (0.49) | HRH3L3MBTL1RAB9AMAPTKDM4E | |
| SCHEMBL2826663 | 0.79 | PTPN11 (0.54) | HRH3L3MBTL1RAB9AP2RY12MAPT | |
| SCHEMBL2829625 | 0.79 | HRH3 (0.54) | HRH3L3MBTL1RAB9AMAPTKDM4E | |
| SCHEMBL2826808 | 0.77 | NPC1 (0.53) | HRH3L3MBTL1RAB9AMAPTPANK3 | |
| SCHEMBL23245962 | 0.77 | HRH3 (0.46) | HRH3L3MBTL1RAB9AMAPTKDM4E | |
| SCHEMBL29618380 | 0.77 | HRH3 (0.46) | HRH3L3MBTL1RAB9AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1824829-B1 | 3-SUBSTITUTED PYRIDINE DERIVATIVES AS H3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-05-05 | — | — | EP | claimed |
| EP-1824829-A1 | 3-SUBSTITUTED PYRIDINE DERIVATIVES AS H3 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2007-08-29 | — | — | EP | claimed |
| US-20060122187-A1 | Pyridine derivatives as H3 antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-08 | — | — | US | claimed |
| WO-2006058649-A1 | 3-SUBSTITUTED PYRIDINE DERIVATIVES AS H3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-08 | — | — | WO | claimed |
| EP-1824829-B1 | 3-SUBSTITUTED PYRIDINE DERIVATIVES AS H3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-05-05 | — | — | EP | disclosed |
| US-7528135-B2 | Pyridine derivatives as H3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1824829-A1 | 3-SUBSTITUTED PYRIDINE DERIVATIVES AS H3 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2007-08-29 | — | — | EP | disclosed |
| US-20060122187-A1 | Pyridine derivatives as H3 antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-08 | — | — | US | disclosed |
| WO-2006058649-A1 | 3-SUBSTITUTED PYRIDINE DERIVATIVES AS H3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122187-A1 | Pyridine derivatives as H3 antagonists | HRH3, HRH4, HRH2 | HRH3 1/4885L3MBTL1 2623/4885RAB9A 2779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.